Skip to main content
SpringerLink
Log in

Anakinra for the treatment of neonatal-onset multisystem inflammatory disease

  • Practice Point
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Agostini L et al. (2004) NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20: 319–325

    Article  CAS  Google Scholar 

  2. Zwerina J et al. (2005) Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann NY Acad Sci 1051: 716–729

    Article  CAS  Google Scholar 

  3. Dinarello C (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355–1359

    Article  CAS  Google Scholar 

  4. Martinon F et al. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237–241

    Article  CAS  Google Scholar 

  5. Hoffman HM et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779–1785

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Allergy and Immunology,

    Hal M Hoffman & Gary S Firestein

  2. Clinical Investigation Institute, both at the University of California, San Diego, USA

    Hal M Hoffman & Gary S Firestein

Authors
  1. Hal M Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary S Firestein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hal M Hoffman.

Ethics declarations

Competing interests

Dr Hoffman is a Consultant for Regeneron Pharmaceuticals.

GS Firestein declared he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffman, H., Firestein, G. Anakinra for the treatment of neonatal-onset multisystem inflammatory disease. Nat Rev Rheumatol 2, 646–647 (2006). https://doi.org/10.1038/ncprheum0350

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0350

  • Springer Nature Limited

This article is cited by

Search

Navigation